Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT ID: NCT04729608
Last Updated: 2023-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
366 participants
INTERVENTIONAL
2021-04-22
2023-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT03639246
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
NCT00479817
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002894
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
NCT00738699
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Batiraxcept+PAC
Combination of batiraxcept and PAC
Batiraxcept
Batiraxcept is an experimental drug
Paclitaxel
Paclitaxel is the standard of care, background therapy
Placebo+PAC
Placebo-controlled arm with PAC
Paclitaxel
Paclitaxel is the standard of care, background therapy
Placebo
Matching placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Batiraxcept
Batiraxcept is an experimental drug
Paclitaxel
Paclitaxel is the standard of care, background therapy
Placebo
Matching placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years or older
* Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1
* Platinum-resistant disease (defined as progression within ≤6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).Subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance.
* Available archived tumor tissue or if archived tissue is not available, a fresh tumor biopsy.
* Received at least 1 but not more than 4 prior therapy regimens.
Note: Maintenance therapy OR hormonal therapies should not be counted as a separate therapy.
Note: Patients who have not received prior bevacizumab must be deemed medically inappropriate OR ineligible to receive bevacizumab, refused to receive bevacizumab, or been unable to receive bevacizumab due to lack of access.
* Measurable disease according to RECIST v1.1 criteria
* Normal gastrointestinal function.
* At least 28 days between termination of prior anticancer or hormonal therapy and first administration of batiraxcept.
* Full recovery from all treatment-related toxicities to Grade 1 or less, except alopecia.
Exclusion Criteria
* Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy for the management of their treated CNS metastases may not be on \>10 mg/day prednisone or equivalent or have demonstrated signs or symptoms of neurologic instability for 28 days or less prior to randomization.
* Primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen)
* Is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer.
* Received prior therapy with PAC in the platinum-resistant recurrent setting
* Evidence of clinically significant third spacing (e.g., pleural effusions, ascites, anasarca, etc.) that requires therapeutic intervention within 28 days prior to first dose of batiraxcept/placebo
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GOG Foundation
NETWORK
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Aravive, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Disney Family Cancer Center
Burbank, California, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
UCLA Women's Health Clinical Research Unit
Los Angeles, California, United States
UC Irvine Health-Chao Family Comprehensive Cancer Center
Orange, California, United States
Stanford Women's Cancer Center
Palo Alto, California, United States
University of California, San Francisco - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Olive View UCLA Medical Center
Sylmar, California, United States
Banner MD Anderson Cancer Center/North Colorado Medical Center
Greeley, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
AdventHealth Gynecologic Oncology
Orlando, Florida, United States
Florida Cancer Specialists
West Palm Beach, Florida, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
Northeast Georgia Medical Center
Gainesville, Georgia, United States
Southeastern Regional Medical Center, LLC
Newnan, Georgia, United States
Lewis Cancer & Research Pavilion at St. Joseph's/Candler Health System, Inc.
Savannah, Georgia, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
North Shore University Health System
Evanston, Illinois, United States
Dr. Sudarshan K. Sharma, Ltd.
Hinsdale, Illinois, United States
Midwestern Regional Medical Center, LLC
Zion, Illinois, United States
Community Health Network
Indianapolis, Indiana, United States
St Vincent Hospital and Healthcare Center
Indianapolis, Indiana, United States
St. Elizabeth Healthcare
Edgewood, Kentucky, United States
Baptist Health Lexington
Lexington, Kentucky, United States
Women's Cancer Care
Covington, Louisiana, United States
Willis-Knighton Physician Network
Shreveport, Louisiana, United States
Maine Medical Partners - Women's Health - Division of Gynecologic Oncology
Scarborough, Maine, United States
Greater Baltimore Medical Center
Baltimore, Maryland, United States
Holy Cross Hospital
Silver Spring, Maryland, United States
Beth Israel Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital
South Weymouth, Massachusetts, United States
Baystate Medical Center
Springfield, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
Cox Health
Springfield, Missouri, United States
Washington University School of Medicine - Division of Gynecologic Oncology
St Louis, Missouri, United States
Mercy Hospital, David C Pratt Cancer Center
St Louis, Missouri, United States
Billings Clinic
Billings, Montana, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States
Center of Hope
Reno, Nevada, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
Optimum Clinical Research Group, LLC
Albuquerque, New Mexico, United States
The Blavatnik Family-Chelsea Medical Center at Mount Sinai
New York, New York, United States
North Shore Hematology Oncology Assoc. DBA NY Cancer and Blood Specialists
Port Jefferson Station, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Stony Brook University Hospital
Stony Brook, New York, United States
Duke Cancer Center
Durham, North Carolina, United States
First Health of the Carolinas
Pinehurst, North Carolina, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
Miami Valley Hospital South
Centerville, Ohio, United States
University of Cincinnati
Cincinnati, Ohio, United States
Ohio State University (OSU) Wexner Medical Center OSU Gynecologic Oncology at Mill Run
Columbus, Ohio, United States
Columbus NCORP
Columbus, Ohio, United States
Kettering Cancer Center
Kettering, Ohio, United States
Stephenson Cancer Center - University of Oklahoma
Oklahoma City, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma, United States
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States
Magee Women's Hospital of UPMC
Pittsburgh, Pennsylvania, United States
West Penn Hospital
Pittsburgh, Pennsylvania, United States
Abington Memorial Hospital, Hanjani Institute for Gyn Onc
Willow Grove, Pennsylvania, United States
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Sanford Gynecology Oncology Clinic
Sioux Falls, South Dakota, United States
Chattanooga's Program in Women's Oncology
Chattanooga, Tennessee, United States
University of Tennessee
Knoxville, Tennessee, United States
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Carilion Clinic Gynecology Oncology
Roanoke, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
West Virginia University
Morgantown, West Virginia, United States
University of Wisconsin Clinical Science Center
Madison, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Pro Healthcare Waukesha Memorial Hospital
Waukesha, Wisconsin, United States
ZNA Middelheim
Antwerp, , Belgium
AZ St Jan Brugge
Bruges, , Belgium
UCL St Luc
Brussels, , Belgium
AZ Maria Middelares
Ghent, , Belgium
UZ Leuven
Leuven, , Belgium
CHA Libramont
Libramont, , Belgium
CHC Liege
Liège, , Belgium
CHU UCL Namur St. Elisabeth
Namur, , Belgium
Sunnybrook Research Institute
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Clinical Research Unit, Jewish General Hospital
Montreal, Quebec, Canada
Peking University Cancer Hospital
Beijing, Haidian District, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang, Hangzhou Province, China
Tianjin Cancer Hospital
Tianjin, Hexi District, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Qilu Hospital Of Shandong University
Jinan, Shandong, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang, Shangcheng District, Hangzhou Province, China
The First Affiliated Hospital of Xi 'an Jiaotong University School of Medicine
Xi’an, Shanxi, China
Nantong Tumor Hospital
Nantong, Tongzhou District, Jiangsu Province, China
The Second Hospital of Shanxi Medical University
Taiyuan, Xinghualing District, Shanxi Province, China
Fudan University Shanghai Cancer Hospital
Shanghai, Xuhui District, China
Hunan Cancer Hospital
Changsha, Yuelu District, Hunan Province, China
Sun Yat-sen Memorial Hospital
Guangzhou, Yuexiu District, Guangdong Province, China
Sun Yat-sen University Cancer Center
Guangzhou, Yuexiu District, China
Fakul Nemocnice Hradec Kralove
Hradec Králové, , Czechia
Fakultni Nemocnice Olomouc
Olomouc, , Czechia
FN Ostrava-Poruba
Ostrava, , Czechia
UG Prague
Prague, , Czechia
ICANS
Strasbourg, , France
LTD High Technology Hospital Medcenter
Batumi, , Georgia
LTD Tbilisi Oncology
Tbilisi, , Georgia
LTD Aversi Clinic
Tbilisi, , Georgia
LTD Consilium Medulla - Multiprofile Clinic
Tbilisi, , Georgia
LTD Caucasus Medical Centre
Tbilisi, , Georgia
LTD Innova
Tbilisi, , Georgia
Policlinico S. Orsola-Malpighi - SSD Oncologia Medica
Bologna, , Italy
Ist. di Candiolo - IRCCS Fondazione del Piemonte per l'Oncologia
Candiolo, , Italy
Ospedale "Vito Fazzi" - ASL Lecce
Lecce, , Italy
SC Oncologia - Ospedale San Luca
Lucca, , Italy
IRCCS Ist. Romagnolo per lo studio dei Tumori "Dino Amadori"
Meldola, , Italy
IEO - Istituto Europeo di Oncologia
Milan, , Italy
IRCCS
Napoli, , Italy
Nuovo Ospedale Santo Stefano di Prato
Prato, , Italy
Fondazione Policlinico "Agostino Gemelli" IRCCS
Rome, , Italy
UCK Centrum Medycyny
Gdansk, , Poland
Szpitale Pomorskie Sp. z o.o.
Gdynia, , Poland
Wojewódzkie Wielospecjalistyczne Centrum Onkologii
Lodz, , Poland
SPSK Nr 2 PUM Klinika Ginekologii Operacyjnej i Onkologii Klinicznej
Szczecin, , Poland
Maria Sklodowska - Curie Instytute Oncolgy Center
Warsaw, , Poland
VHIO
Barcelona, , Spain
Hospital San Pedro de Alcántara
Cáceres, , Spain
Hospital Universitario Reina Sofia (Provincial)
Córdoba, , Spain
Hospital General Universitario de Elche
Elche, , Spain
Institut Catala d'Oncologia
Girona, , Spain
ICO
L'Hospitalet de Llobregat, , Spain
Clinica Universidad de Navarra
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital Son Espases
Palma de Mallorca, , Spain
Clinica Universidad de Navarra
Pamplona, , Spain
IVO (Instituto Valenciano de Oncología)
Valencia, , Spain
Royal United Hospital Bath NHS Foundation Trust
Bath, , United Kingdom
Clatterbridge Cancer Centre
Liverpool, , United Kingdom
The Royal Marsden NHS Foundation Trust (Sutton)
London, , United Kingdom
The Royal Marsden NHS Foundation Trust (Fulham Road)
London, , United Kingdom
South West Wales Cancer Institute
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GOG-3059
Identifier Type: OTHER
Identifier Source: secondary_id
ENGOT OV66
Identifier Type: OTHER
Identifier Source: secondary_id
AXLerate-OC
Identifier Type: OTHER
Identifier Source: secondary_id
AVB500-OC-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.